Global Epirubicin Hydrochloride Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Epirubicin Hydrochloride Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Epirubicin Hydrochloride is the hydrochloride salt of the 4'-epi-isomer of the anthracycline antineoplastic antibiotic doxorubicin. Epirubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis. This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation.
Epirubicin Hydrochloride report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Epirubicin Hydrochloride market is projected to reach US$ 211.1 million in 2034, increasing from US$ 253.2 million in 2022, with the CAGR of -2.5% during the period of 2024 to 2034. Demand from Cancer and Others are the major drivers for the industry.
Global core Epirubicin Hydrochloride players include Synbias Pharma, Zhejiang Hisun Pharma and Pfizer etc. The top 3 companies hold a share about 60%. Asia-Pacific is the largest market, with a share about 45%, followed by Europe and North America with the share about 25% and 20%.
In terms of product, 10mg/5ml is the largest segment, with a share about 45%, followed by 50mg/25ml, with a share about 40%. And in terms of application, the largest application is cancer, with a share about 95%, followed by others, with a share about 5%.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Epirubicin Hydrochloride market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Sterling Biotech
Zhejiang Hisun Pharma
Flavine
Teva API
Microbiopharm Japan
DZD Heze Pharma
Synbias Pharma
Intas Pharma
Humble Healthcaare
Lunan Pharmaceutical Group
Pfizer
Beijing Union Pharmaceutical Factory
Segment by Type
10mg/5ml
50mg/25ml
Other
Cancer
Others
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Epirubicin Hydrochloride market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Epirubicin Hydrochloride, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Epirubicin Hydrochloride industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Epirubicin Hydrochloride in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Epirubicin Hydrochloride introduction, etc. Epirubicin Hydrochloride Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Epirubicin Hydrochloride market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Epirubicin Hydrochloride report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Epirubicin Hydrochloride market is projected to reach US$ 211.1 million in 2034, increasing from US$ 253.2 million in 2022, with the CAGR of -2.5% during the period of 2024 to 2034. Demand from Cancer and Others are the major drivers for the industry.
Global core Epirubicin Hydrochloride players include Synbias Pharma, Zhejiang Hisun Pharma and Pfizer etc. The top 3 companies hold a share about 60%. Asia-Pacific is the largest market, with a share about 45%, followed by Europe and North America with the share about 25% and 20%.
In terms of product, 10mg/5ml is the largest segment, with a share about 45%, followed by 50mg/25ml, with a share about 40%. And in terms of application, the largest application is cancer, with a share about 95%, followed by others, with a share about 5%.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Epirubicin Hydrochloride market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Sterling Biotech
Zhejiang Hisun Pharma
Flavine
Teva API
Microbiopharm Japan
DZD Heze Pharma
Synbias Pharma
Intas Pharma
Humble Healthcaare
Lunan Pharmaceutical Group
Pfizer
Beijing Union Pharmaceutical Factory
Segment by Type
10mg/5ml
50mg/25ml
Other
Segment by Application
Cancer
Others
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Epirubicin Hydrochloride market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Epirubicin Hydrochloride, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Epirubicin Hydrochloride industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Epirubicin Hydrochloride in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Epirubicin Hydrochloride introduction, etc. Epirubicin Hydrochloride Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Epirubicin Hydrochloride market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices